Advertisement


Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial (Spanish Language Version)

2017 Gastrointestinal Cancers Symposium

Advertisement

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses in Spanish study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).



Related Videos

Pancreatic Cancer

Sarah E. Hoffe, MD, on Pancreatic Cancer and SBRT: Pros and Cons

Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.

Colorectal Cancer

Brendan J. Guercio, MD, on Colorectal Cancer and Physical Activity: Impact on Survival

Brendan J. Guercio, MD, of the Dana-Farber Cancer Institute, discusses results from a study of patients with metastatic colorectal cancer who took part in weekly physical activity and its impact on their disease progression and overall survival (Abstract 659).

Gastrointestinal Cancer

Salah-Eddin Al-Batran, MD, on Gastric Cancer: RADPAC Trial Results

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses study findings on paclitaxel with and without RAD001 in patients with gastric cancer whose disease has progressed after therapy with a fluoropyrimidine/platinum-containing regimen (Abstract 4).

Colorectal Cancer

Cornelis van de Velde, MD, PhD, on Rectal Cancer: A Database Update

Cornelis van de Velde, MD, PhD, of Leiden University Medical Center, discusses the International Watch & Wait database, established to track evidence on organ-preserving strategies in patients with rectal cancer (Abstract 521).

For More Information: www.IWWD.org

Pancreatic Cancer
Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

Advertisement

Advertisement



Advertisement